Scott Rocklage: Investor, Leader, and Researcher

Doctor Scott Rocklage is a businessman and a medical researcher. He is also an inventor. He has a number of different patents under his name.

Employment

Rocklage has over 20 years of work experience in the health field. He has had many executive positions over the past two decades. He was the chairman of both Ilypsa and Miikana. Both were eventually purchased by Amgen and Entremed respectively.

In 2003 Rocklage was named a venture partner at 5AM Ventures. In 2004 he was made a managing partner at the company. The business is a venture capital firm that invests in new companies that are involved in the field of biology.

He is presently the chairman of the boards of Cidara Therapeutics and Novira Therapeutics. He also sits on the board of Epirus, Kinestral, Pulmatrix, and Rennovia. Rocklage currently works out of the 5AM Ventures offices in Massachusetts.

Education

After he graduated from high school, Rocklage attended the University of California, Berkeley where he earned a bachelor’s degree in chemistry. He concluded his education by earning his Ph.D. in chemistry from the Massachusetts Institute of Technology. Additionally, he conducted scientific research under the tutelage of Richard Schrock who is most known as a Nobel Prize winner.

Accomplishments

Scott Rocklage has also authored over 100 research papers that have been published in peer-reviewed publications. His leadership skills are sometimes credited for a number of different new drugs being approved by the FDA (Food and Drugs Administration). They include Omniscan and Teslascan. He is also given credit for half a dozen other drugs being placed into clinical trials.

More About Rocklage

Rocklage believes that he has been able to bring ideas into reality and develop innovative medicine by working with a number of entrepreneurs, physicians, and scientists. He once stated in an interview that it was his organizational skills that led to his productivity.

He continues to be excited by the developments in cancer treatment because of what they could lead to in the future. His personal advice to entrepreneurs today is to welcome taking risks because it is better than just being employed by an established corporation.